Mankind Pharma Ltd. (IN:MANKIND)

:MANKIND

MANKIND

Mankind Pharma Ltd.

RESEARCH TOOLSreports

Want to see IN:MANKIND full AI Analyst Report?

Mankind Pharma Ltd. (MANKIND) Price & Analysis

14 Followers

MANKIND Stock Chart & Stats

₹2202.55

-₹40.15(-1.38%)

At close: Jan 08 4:00 PM EST

₹2202.55

-₹40.15(-1.38%)

Day’s Range― - ―

52-Week Range₹1,909.90 - ₹2,726.75

Previous CloseN/A

Volume302.66K

Average Volume (3M)10.08K

Market Cap

₹1.07T

Enterprise Value₹1.12T

Total Cash (Recent Filing)₹31.05B

Total Debt (Recent Filing)₹83.69B

Price to Earnings (P/E)55.5

Beta0.49

Next Earnings

Aug 05, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.04%

Share Statistics

EPS (TTM)42.77

Shares Outstanding412,828,340

10 Day Avg. Volume5,924

30 Day Avg. Volume10,081

Financial Highlights & Ratios

PEG Ratio-7.55

Price to Book (P/B)5.08

Price to Sales (P/S)5.80

P/FCF Ratio43.81

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹2,820.00

Price Target Upside28.03% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)55.75

Revenue Forecast (FY)₹159.34B

Bulls Say, Bears Say

Bulls Say

Consistent Revenue GrowthMulti-year, consistent revenue growth demonstrates durable demand, effective field-force distribution and brand traction in domestic prescription and OTC markets. This predictability supports capacity planning, reinvestment in brands and R&D, and underpins medium-term earnings visibility.

Healthy Profitability MarginsSustained mid-teens net margins and near-20% EBIT reflect structural pricing power from branded formulations and disciplined cost control. Even after some compression, these margins provide a stable cushion to fund operations, dividends and reinvestment versus lower-margin peers.

Positive Free Cash FlowMaterial free cash flow coverage of earnings indicates the business reliably generates cash to service debt, fund capex and support dividends or brand investment. Strong FCF enhances financial flexibility and reduces reliance on external financing over the medium term.

Bears Say

Margin CompressionNotable year-over-year margin contraction suggests rising input costs, pricing pressure or adverse product mix. If structural, continued compression will erode free cash flow and ROE, forcing tougher allocation choices and potentially weakening long-term competitive investment.

Weak Cash ConversionOperating cash flow at roughly 39% of reported net income signals earnings quality and working-capital issues. Persistent weak cash conversion raises the risk that reported profits don't translate to spendable cash, constraining dividends, capex or debt paydown despite accounting profits.

Higher Debt Vs Historical LevelsAlthough leverage has improved recently, overall debt remains elevated relative to earlier periods, reducing balance-sheet flexibility. Higher indebtedness combined with a downtrending ROE limits strategic optionality and increases sensitivity to interest or cash-flow shocks.

Mankind Pharma Ltd. News

Mankind Pharma Secures High CARE Ratings for ₹1,000 Crore Bank Facilities

An announcement from Mankind Pharma Ltd. ( ($IN:MANKIND) ) is now available. Mankind Pharma Limited has announced that...

29d ago

Mankind Pharma Publishes Q3 and Nine-Month FY26 Earnings Call Transcript

The latest update is out from Mankind Pharma Ltd. ( ($IN:MANKIND) ). Mankind Pharma Limited has released the...

3M ago

Mankind Pharma Challenges GST Order on Subsidiary Merger

Mankind Pharma Ltd. ( ($IN:MANKIND) ) just unveiled an announcement. Mankind Pharma Ltd. has announced that it received...

6M ago

Mankind Pharma Reports Strong Financial Performance for Q2 and H1 2025

The latest update is out from Mankind Pharma Ltd. ( ($IN:MANKIND) ). Mankind Pharma Ltd. announced its unaudited...

7M ago

Mankind Pharma Receives ESG Rating Score of 69

Mankind Pharma Ltd. ( ($IN:MANKIND) ) has issued an update. Mankind Pharma Ltd. has received an ESG rating...

7M ago

Mankind Pharma Schedules Investor Conference Call for Q2 & H1 FY26

An update from Mankind Pharma Ltd. ( ($IN:MANKIND) ) is now available. Mankind Pharma Limited has announced an...

7M ago

Mankind Pharma’s MKP10241 Study: A Potential Game-Changer for Obesity and Diabetes Treatment?

Mankind Pharma Ltd. (($IN:MANKIND)) announced an update on their ongoing clinical study. Mankind Pharma Ltd. is conducting a...

7M ago

Mankind Pharma Reports No Share Dematerialisation Requests for Q3 2025

Mankind Pharma Ltd. ( ($IN:MANKIND) ) has provided an announcement. Mankind Pharma Limited has announced that it has...

8M ago

Mankind Pharma Ltd. Sees Withdrawal of CGST Penalty

An announcement from Mankind Pharma Ltd. ( ($IN:MANKIND) ) is now available. Mankind Pharma Ltd. announced that the...

8M ago

Mankind Pharma to Engage with Investors at Jefferies India Forum

Mankind Pharma Ltd. ( ($IN:MANKIND) ) has provided an update. Mankind Pharma Ltd. has announced its participation in...

8M ago

MANKIND FAQ

What was Mankind Pharma Ltd.’s price range in the past 12 months?

Mankind Pharma Ltd. lowest stock price was ₹1909.90 and its highest was ₹2726.75 in the past 12 months.

What is Mankind Pharma Ltd.’s market cap?

Mankind Pharma Ltd.’s market cap is ₹1.07T.

When is Mankind Pharma Ltd.’s upcoming earnings report date?

Mankind Pharma Ltd.’s upcoming earnings report date is Aug 05, 2026 which is in 76 days.

How were Mankind Pharma Ltd.’s earnings last quarter?

Mankind Pharma Ltd. released its earnings results on May 19, 2026. The company reported ₹14 earnings per share for the quarter, beating the consensus estimate of ₹10.15 by ₹3.85.

Is Mankind Pharma Ltd. overvalued?

According to Wall Street analysts Mankind Pharma Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mankind Pharma Ltd. pay dividends?

Mankind Pharma Ltd. pays a Notavailable dividend of ₹1 which represents an annual dividend yield of 0.04%. See more information on Mankind Pharma Ltd. dividends here

What is Mankind Pharma Ltd.’s EPS estimate?

Mankind Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Mankind Pharma Ltd. have?

Mankind Pharma Ltd. has 412,828,340 shares outstanding.

What happened to Mankind Pharma Ltd.’s price movement after its last earnings report?

Mankind Pharma Ltd. reported an EPS of ₹14 in its last earnings report, beating expectations of ₹10.15. Following the earnings report the stock price went down -0.09%.

Which hedge fund is a major shareholder of Mankind Pharma Ltd.?

Currently, no hedge funds are holding shares in IN:MANKIND

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Mankind Pharma Ltd.

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, and respiratory diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. The company offers its products primarily under the Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar brand names. In addition, it engages in the trading and exporting of pharmaceutical and health care products; manufacturing of packing materials ayurvedic products, packing materials, bulk drugs, and consumer goods; real estate, leasing, and hospitality businesses; and provision of IT services. Mankind Pharma Limited was founded in 1986 and is based in New Delhi, India.

Mankind Pharma Ltd. (MANKIND) Earnings & Revenues

Historic Earnings Reports

MANKIND Stock 12 Month Forecast

Average Price Target

₹2,820.00

▲(28.03% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2000":"₹2,000","3001":"₹3,001","2250.25":"₹2,250.3","2500.5":"₹2,500.5","2750.75":"₹2,750.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹3.00K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2820,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹2.82K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2640,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹2.64K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2000,2250.25,2500.5,2750.75,3001],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2246.55,2304.5076923076927,2362.4653846153847,2420.423076923077,2478.380769230769,2536.3384615384616,2594.296153846154,2652.253846153846,2710.2115384615386,2768.169230769231,2826.126923076923,2884.0846153846155,2942.0423076923075,{"y":3000,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2246.55,2290.661538461539,2334.773076923077,2378.8846153846157,2422.996153846154,2467.1076923076926,2511.2192307692308,2555.3307692307694,2599.4423076923076,2643.5538461538463,2687.6653846153845,2731.776923076923,2775.8884615384613,{"y":2820,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2246.55,2276.8153846153846,2307.0807692307694,2337.346153846154,2367.6115384615387,2397.876923076923,2428.142307692308,2458.4076923076923,2488.673076923077,2518.9384615384615,2549.2038461538464,2579.4692307692308,2609.7346153846156,{"y":2640,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2462.73,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2413.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2287.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2561.29,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2518.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2438.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2382.35,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2229.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2163.1,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2067.1,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2244.95,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2001.15,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2246.55,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >